Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

P-glycoprotein (human) monoclonal antibody (JSB-1)

ALX-801-004-C100 100 µg 1,002.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:ABCB1, CD243, P-glycoprotein 1
Immunogen:MDR (multidrug resistant) Chinese hamster ovary cells (ChrC5).
UniProt ID:P08183
Species reactivity:Human
Chinese hamster
Specificity:Recognizes a highly conserved cytoplasmic epitope of the human P-glycoprotein, the expression of which is strongly correlated with the degree of MDR derived MDR cell lines and human MDR cell lines from lung, ovaries and B cell lymphoma.
Crossreactivity:Does not cross-react with mouse, rat or guinea pig P-glycoprotein.
Applications:Flow Cytometry, ICC, IHC (FS), IHC (PS), WB
Recommended Dilutions/Conditions:Flow Cytometry (at least 1:10)
Immunocytochemistry (acetone-fixed cell preparation at least 1:20)
Immunohistochemistry (acetone-fixed frozen sections at least 1:20, formalin-fixed paraffin sections 1:20)
Western Blot (start optimizing working dilution at 1:10)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Formulation:Liquid. In PBS containing 0.1% BSA and 0.02% sodium azide.
Handling:Avoid freeze/thaw cycles.
Shipping:Blue Ice
Short Term Storage:+4°C
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
P-glycoprotein (human) monoclonal antibody (JSB-1) image
Figure: Liver cells stained with JSB-1 (ALX-801-004).
Please mouse over
P-glycoprotein (human) monoclonal antibody (JSB-1) image

Product Literature References

P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study: M. Feldmann, et al.; Lancet Neurol. 12, 777 (2013), Application(s): IHC using brain tissue, Abstract;
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma: H.M. Coley, et al.; Eur. J. Cancer 36, 881 (2000), Abstract;
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma: A.P. Jillella, et al.; Cancer Invest. 18, 609 (2000), Abstract;
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000), Abstract; Full Text
Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia: S. Poulain, et al.; Adv. Exp. Med. Biol. 457, 57 (1999), Abstract;
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia: M.R. Grey, et al.; Leuk. Res. 23, 29 (1999), Abstract;
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors: T. Sawada, et al.; Brain Tumor Pathol. 16, 23 (1999), Abstract;
Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol. 52, 450 (1999), Abstract;
Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer Res. Clin. Oncol. 125, 117 (1999), Abstract;
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy: R.E. Jimenez, et al.; Cancer 86, 976 (1999), Abstract;
Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma: Y.S. Kim, et al.; Clin. Nucl. Med. 24, 874 (1999), Abstract;
The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein: S. Barg, et al.; PNAS 96, 5539 (1999), Abstract; Full Text
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies: F.J. Lacueva, et al.; Histopathology 32, 328 (1998), Abstract;
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol. 103, 1083 (1998), Abstract;
Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42: E. Moran, et al.; Eur. J. Cancer 33, 652 (1997), Abstract;
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy: S. Chevillard, et al.; Cancer 77, 292 (1996), Abstract;
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome: N. Baldini, et al.; N. Engl. J. Med. 333, 1380 (1995), Abstract;
Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase: V.V. Rao, et al.; J. Histochem. Cytochem. 43, 1187 (1995), Abstract;
Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma: M. Itsubo, et al.; Cancer 73, 298 (1994), Abstract;
New immunohistochemical "sandwich" staining method for mdr1 P- glycoprotein detection with JSB-1 monoclonal antibody in formalin- fixed, paraffin-embedded human tissues: K. Toth, et al.; Am. J. Pathol. 144, 227 (1994), Abstract;
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse: F.A. Sinicrope, et al.; Cancer 74, 2908 (1994), Abstract;
Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies: J.L. Gala, et al.; J. Clin. Pathol. 47, 619 (1994), Abstract;
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy: T.M. Grogan, et al.; Blood 81, 490 (1993), Abstract;
Flow cytometric analysis of P-glycoprotein in normal and leukemic cells: M.I. Tiirikainen, et al.; Ann. Hematol. 65, 124 (1992), Abstract;
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991), Abstract;
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy: W.S. Dalton, et al.; J. Clin. Oncol. 7, 415 (1989), Abstract;
Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies: H. Hamada & T. Tsuruo; PNAS 83, 7785 (1986), Abstract;

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
P-glycoprotein Monoclonal antibody
By catalog section:


Technical Service
Customer Service